Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Marcelin AG, Lamotte C, Delaugerre C, Ktorza N, Ait Mohand H, Cacace R, Bonmarchand M, Wirden M, Simon A, Bossi P, Bricaire F, Costagliola D, Katlama C, Peytavin G, Calvez V; Genophar Study Group. Marcelin AG, et al. Among authors: lamotte c. Antimicrob Agents Chemother. 2003 Feb;47(2):594-600. doi: 10.1128/AAC.47.2.594-600.2003. Antimicrob Agents Chemother. 2003. PMID: 12543665 Free PMC article. Clinical Trial.
High indinavir plasma concentrations in HIV-positive patients co-infected with hepatitis B or C virus treated with low doses of indinavir and ritonavir (400/100 mg twice a day) plus two nucleoside reverse transcriptase inhibitors.
Bossi P, Peytavin G, Lamotte C, Calvez V, Bricaire F, Costagliola D, Katlama C. Bossi P, et al. Among authors: lamotte c. AIDS. 2003 May 2;17(7):1108-10. doi: 10.1097/00002030-200305020-00030. AIDS. 2003. PMID: 12700471 Clinical Trial. No abstract available.
Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Marcelin AG, Dalban C, Peytavin G, Lamotte C, Agher R, Delaugerre C, Wirden M, Conan F, Dantin S, Katlama C, Costagliola D, Calvez V. Marcelin AG, et al. Among authors: lamotte c. Antimicrob Agents Chemother. 2004 Dec;48(12):4687-92. doi: 10.1128/AAC.48.12.4687-4692.2004. Antimicrob Agents Chemother. 2004. PMID: 15561845 Free PMC article.
Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir.
Duval X, Lamotte C, Race E, Descamps D, Damond F, Clavel F, Leport C, Peytavin G, Vilde JL. Duval X, et al. Among authors: lamotte c. Antimicrob Agents Chemother. 2002 Feb;46(2):570-4. doi: 10.1128/AAC.46.2.570-574.2002. Antimicrob Agents Chemother. 2002. PMID: 11796381 Free PMC article.
Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial.
Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-Vézinet F, Clavel F, Girard PM; Narval Trial Group. Meynard JL, et al. Among authors: lamotte c. AIDS. 2002 Mar 29;16(5):727-36. doi: 10.1097/00002030-200203290-00008. AIDS. 2002. PMID: 11964529 Clinical Trial.
Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.
Marcelin AG, Cohen-Codar I, King MS, Colson P, Guillevic E, Descamps D, Lamotte C, Schneider V, Ritter J, Segondy M, Peigue-Lafeuille H, Morand-Joubert L, Schmuck A, Ruffault A, Palmer P, Chaix ML, Mackiewicz V, Brodard V, Izopet J, Cottalorda J, Kohli E, Chauvin JP, Kempf DJ, Peytavin G, Calvez V. Marcelin AG, et al. Among authors: lamotte c. Antimicrob Agents Chemother. 2005 May;49(5):1720-6. doi: 10.1128/AAC.49.5.1720-1726.2005. Antimicrob Agents Chemother. 2005. PMID: 15855487 Free PMC article. Clinical Trial.
81 results